Advances in pulmonary vasodilator therapies such as prostacyclin analogs, prostacyclin receptor agonists, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and/or soluble guanylate cyclase stimulators have improved the prognosis of pulmonary arterial hypertension (PAH)3. The gene discussed is PTGIR; the disease is pulmonary arterial hypertension.